AI Stock Analysis - Catalyst Pharmaceuticals (CPRX)
Analysis generated August 11, 2025.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of unique and innovative treatments for rare neurological diseases and disorders. Their flagship product, Firdapse, is a significant treatment targeted at Lambert-Eaton Myasthenic Syndrome (LEMS). The company seeks to leverage its proprietary drug development and sales platforms to expand its portfolio, offering new hope to patients with debilitating ailments.
Stock Alerts - Catalyst Pharmaceuticals (CPRX)
 |
Catalyst Pharmaceuticals | December 17 Insider Alert: Harper Molly is selling shares |
|
Catalyst Pharmaceuticals | November 29 Insider Alert: Del Carmen Jeffrey is selling shares |
|
Catalyst Pharmaceuticals | November 15 Insider Alert: Elsbernd Brian is selling shares |
|
Catalyst Pharmaceuticals | November 11 Price is up by 6.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Catalyst Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 22 | Sign up | Sign up | Sign up |
| Facebook Followers | 3,108 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,783 | Sign up | Sign up | Sign up |
| X Followers | 869 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 66 | Sign up | Sign up | Sign up |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
| Price | $24.07 |
| Target Price | Sign up |
| Volume | 779,930 |
| Market Cap | $2.9B |
| Year Range | $19.13 - $26.31 |
| Dividend Yield | 0% |
| PE Ratio | 13.79 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”January 16 - Yahoo Entertainment |
|
 |
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 12 - SeekingAlpha |
|
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 12 - SeekingAlpha |
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap CompaniesJanuary 8 - GlobeNewswire |
|
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)January 5 - GlobeNewswire |
|
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular DystrophyJanuary 14 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 148M | 25M | 123M | 53M | 80M | 0.420 |
| Q2 '25 | 147M | 30M | 117M | 52M | 79M | 0.410 |
| Q1 '25 | 141M | 18M | 124M | 57M | 73M | 0.450 |
| Q4 '24 | 142M | 22M | 120M | 56M | 72M | 0.440 |
| Q3 '24 | 129M | 19M | 109M | 44M | 51M | 0.350 |
Insider Transactions View All
| Harper Molly filed to sell 2,360 shares at $23.1. December 16 '25 |
| Harper Molly filed to sell 9,106 shares at $23.7. December 16 '25 |
| Harper Molly filed to sell 13,579 shares at $23.2. December 16 '25 |
| Del Carmen Jeffrey filed to sell 3,962 shares at $23.3. November 28 '25 |
| Elsbernd Brian filed to sell 231,039 shares at $22.7. November 14 '25 |
Similar companies
Read more about Catalyst Pharmaceuticals (CPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & business outlook.
FAQ - Catalyst Pharmaceuticals
The Market Cap of Catalyst Pharmaceuticals is $2.9B.
As of today, Catalyst Pharmaceuticals' PE (Price to Earnings) ratio is 13.79.
Currently, the price of one share of Catalyst Pharmaceuticals stock is $24.07.
The CPRX stock price chart above provides a comprehensive visual representation of Catalyst Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Catalyst Pharmaceuticals shares. Our platform offers an up-to-date CPRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Catalyst Pharmaceuticals (CPRX) does not offer dividends to its shareholders. Investors interested in Catalyst Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Catalyst Pharmaceuticals are Amgen, Gilead Sciences, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
